AI Article Synopsis
- - Brain metastasis from colorectal cancer is rare and typically has a poor prognosis, making treatment challenging.
- - The primary treatment for brain metastasis is radiotherapy, while systemic options include targeted therapies and chemotherapy, but their effectiveness on brain metastasis is not fully proven.
- - A case is reported where a patient with brain metastasis from colorectal cancer showed significant improvement after receiving a combination of capecitabine, oxaliplatin, and cetuximab.
Article Abstract
Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171034 | PMC |
| http://dx.doi.org/10.2217/cns-2023-0004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!